Navigation Links
Drug shown to reverse radioiodine resistance in some advanced thyroid cancers
Date:2/13/2013

NEW YORK, FEBRUARY 13, 2013 The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan-Kettering Cancer Center.

Published in the February 14 issue of the New England Journal of Medicine, the study offers new hope for patients with a disease that can have a poor prognosis. An estimated 56,000 new cases of thyroid cancer are diagnosed each year in the United States, and that number is on the rise, according to the National Cancer Institute. About 5 percent of these patients will eventually develop distant metastatic disease, and the ten-year survival rate for patients with metastatic tumors that fail to respond to RAI is approximately 10 percent.

According to James A. Fagin, MD, Memorial Sloan-Kettering's Endocrinology Service Chief and senior author on the study, many trials have tested strategies for overcoming RAI resistance in metastatic thyroid cancers, but none have been successful. Previous studies have shown that a cell's ability to absorb RAI is controlled by the MAPK pathway, so Dr. Fagin and his colleagues examined whether selumetinib, an MAPK inhibitor, could reverse RAI resistance by inhibiting the signaling of genetic mutations in this pathway. The approach proved effective, especially in patients with thyroid cancers that contain a mutation in the RAS gene a component of the MAPK pathway.

"Blocking this key pathway increased the uptake of iodine, making radioiodine treatment potentially effective once again," said Fagin, who led this research in cells and in mice.

Following a five-day low-iodine diet, researchers administered selumetinib to 20 patients with tumors resistant to radioiodine. After four weeks, patients underwent a diagnostic scan that measured how much RAI their tumors would absorb. In eight patients, including all five with an
'/>"/>

Contact: Caitlin Hool
HOOLC@MSKCC.ORG
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Community-based nutrition education shown to be successful in increasing calcium intake
2. Compounds shown to thwart stubborn pathogens social propensity
3. Antioxidant shown to reduce blindness risk in extremely premature babies
4. Vitamin D with calcium shown to reduce mortality in elderly
5. Gallbladder shown as potential stem cell source for regenerative liver and metabolic disease
6. Pycnogenol (French maritime pine bark extract) shown to improve menopause symptoms in new study
7. Promising compound restores memory loss and reverses symptoms of Alzheimers
8. Scripps Florida scientists design molecule that reverses some fragile X syndrome defects
9. BUSM researchers find potential key to halt progression, reverse damage from emphysema
10. Medusa reimagined: Caltech-led team reverse engineers a jellyfish with the ability to swim
11. Drug could reverse scourge of cerebral malaria for survivors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... As climate change shifts the geographic ranges in which ... it has on their parasites. Does an increased range ... as well? , Not necessarily, says a team of ... Armand Kuris. In a study published in the ... that for some species, the opposite may happen: Hosts ...
(Date:7/9/2014)... Emerging fungal pathogens pose a greater threat ... population declines of amphibians, bats, corals, bees and ... Florida published in the prestigious journal Nature ... immunological resistance to a deadly chytrid fungus implicated ... resistance is important because it is the basis ...
(Date:7/9/2014)... with traumatic injuries have identified an immune marker ... a hospital-acquired infection. The study, led by clinician-scientists ... June in the journal Shock , is ... to the clinical implementation of quick-turnaround immune function ... system damage following critical illness or injury in ...
Breaking Biology News(10 mins):Not at home on the range 2Not at home on the range 3Not at home on the range 4USF study: Amphibians can acquire resistance to deadly fungus 2Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
... biologists is figuring out which among the hundreds of genetic ... driving the cancer,s spread. Using a new technique ... that appears to drive progression of small cell lung cancer, ... percent of lung cancer cases. The gene, which ...
... Foundation has awarded Delft University of Technology (TU Delft, the ... project is to develop new technology for processing human waste ... costs affordable to the poor in developing countries. ... at the AfricaSan conference in Rwanda (www.africasan3.com) as part of ...
... Knowing how trees grow and how they age may ... warmer climate, for instance, and other changes. Little is known, ... tree growth. "Although much research has been done on how ... increase in size," says research ecologist Frederick (Rick) Meinzer, "structure ...
Cached Biology News:New lung-cancer gene found 2Reinventing the toilet for safe and affordable sanitation 2
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
(Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... target drug delivery. , ... Cary, NC (PRWEB) October ... company ) and Auburn University announced today a joint research project ... Veterinary Medicine,s Department of Pathobiology, the six-month study is under the ...
... 2008 5:00 p.m. EST, HOPKINTON, Mass., Oct. ... ) will conduct a conference call discussing the,company,s ... EST on Monday,November 10. Kevin Hrusovsky, President and ... will host the call. Management will,discuss operational and ...
... Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ), a clinical-stage ... novel medicines in the areas of,hepatitis C and ... the third quarter ended September 30, 2008., ... of our hepatitis C,development programs," said Steve Worland ...
Cached Biology Technology:Calvert Research and Auburn University Announce Joint Venture 2Calvert Research and Auburn University Announce Joint Venture 3Caliper Life Sciences' Third Quarter 2008 Financial Results Conference Call Notice 2Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 2Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 3Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 4Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 5Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 6Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 7Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights 8
...
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
... The NEW HandyStep electronic from BRAND ... pipetting. It is the only electronic, ... standard syringe tips, including BRAND PD-Tip ... Plus, Fisherbrand Dispenser Tips,and VWRbrand Combi-Syringes. ...
Biology Products: